DDInter1652 DDInter160
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis.
Bacillus calmette-guerin substrain tice live antigen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Budesonide
Bacillus calmette-guerin substrain tice live antigen {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Bacillus calmette-guerin substrain tice live antigen {u} may lead to a major life threatening interaction when taken with {v} Ocrelizumab
Bacillus calmette-guerin substrain tice live antigen may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Etanercept
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Ocrelizumab